<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03452605</url>
  </required_header>
  <id_info>
    <org_study_id>T1DCFMRI</org_study_id>
    <nct_id>NCT03452605</nct_id>
  </id_info>
  <brief_title>The Effect of Cocoa Flavanol on the BOLD Response and Cognitive Function in Type 1 Diabetes</brief_title>
  <official_title>Effect of Acute Cocoa Flavanol Intake on the BOLD Response and Cognitive Function in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vrije Universiteit Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vrije Universiteit Brussel</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 Diabetes (T1D) is associated with microvascular changes in the brain, which can cause&#xD;
      cognitive dysfunction. Cocoa flavanols (CF) can stimulate vasodilation, resulting in enhanced&#xD;
      cerebral blood flow and better cognitive function. This study aimed to investigate whether&#xD;
      acute CF supplementation can improve cognitive function and the hemodynamic (BOLD) response&#xD;
      in T1D patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2015</start_date>
  <completion_date type="Actual">March 15, 2017</completion_date>
  <primary_completion_date type="Actual">March 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cognitive function</measure>
    <time_frame>5 min</time_frame>
    <description>reaction time (milliseconds) on the flanker task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BOLD fmri response</measure>
    <time_frame>5 min</time_frame>
    <description>blood oxygenation level dependent response during flanker test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>high cocoa flavanol drink</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high cocoa flavanol drink (900 mg cocoa flavanol dissolved in 300 ml skimmed milk) 2h pre-fMRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low cocoa flavanol drink</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>low cocoa flavanol drink (30 mg cocoa flavanol dissolved in 300 ml skimmed milk), matched for theobromine, caffeine and macronutrients with the high cocoa flavanol drink 2h-pre fMRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cocoa flavanol supplementation</intervention_name>
    <description>cocoa flavanols (containing 196 mg epicatechin)</description>
    <arm_group_label>high cocoa flavanol drink</arm_group_label>
    <arm_group_label>low cocoa flavanol drink</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  non-smoking T1D patients or matched healthy controls&#xD;
&#xD;
          -  having diabetes for more than 1 year&#xD;
&#xD;
          -  males and females older than 18 years&#xD;
&#xD;
          -  stable medications for more than 6 months (no use of cholinesterase inhibitors or&#xD;
             prior use of multivitamins was allowed)&#xD;
&#xD;
          -  adequate visual and auditory acuity to allow neuropsychological testing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  participant enrolled in any investigational drug study within 2 months or longer,&#xD;
             depending on the investigational drug half-life&#xD;
&#xD;
          -  history in the past 2 years of epileptic seizures or any major psychiatric disorder&#xD;
&#xD;
          -  history or MRI evidence of brain damage, including significant trauma, stroke,&#xD;
             hydrocephalus, mental retardation, or serious neurological disorder,&#xD;
&#xD;
          -  significant history of alcoholism or drug abuse&#xD;
&#xD;
          -  unstable cardiac, renal, lung, liver, or other severe chronic disease&#xD;
&#xD;
          -  hypertension (systolic blood pressure ≥160 mmHg, diastolic blood pres-sure ≥100 mmHg)&#xD;
             or hypotension (systolic blood pressure &lt;100 mmHg)&#xD;
&#xD;
          -  pacemaker or other medical metal devices that precludes performing MRI,&#xD;
&#xD;
          -  chronic inflammatory diseases, including lupus, rheumatoid arthritis, or polymyalgia&#xD;
             rheumatic&#xD;
&#xD;
          -  macrovascular complications&#xD;
&#xD;
          -  retinopathy, nephropathy or neuropathy (microvascular complications)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2018</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vrije Universiteit Brussel</investigator_affiliation>
    <investigator_full_name>Romain Meeusen</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

